/PRNewswire/ Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, today.
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Apr 13, 2021 11:05am Kyverna is working on T-cell therapies for autoimmune diseases that could be safer and last longer than current options. (Paul Bright / Unsplash)
James Chung (Kyverna Therapeutics)
James Chung, a longtime Amgen executive who led global clinical development for autoimmune drug Enbrel, has a new gig. He joins Kyverna Therapeutics as chief medical officer as the company sets its sights on the clinic.
Chung, who holds an M.D. and a Ph.D., arrives after more than 16 years at Amgen. He was most recently head of inflammation and neuroscience in Amgen’s global medical organization and global development leader for Enbrel, a drug approved for several autoimmune diseases including rheumatoid arthritis, plaque psoriasis and ankylosing spondylitis.